CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: Experience of the society of abdominal radiology prostate cancer disease-focused panel
Authors
Jordan M. Anaokar
Sandeep Arora
+31 more
Nimrod S. Barashi
Jelle O. Barentsz
Tharakeswara K. Bathala
Leonardo K. Bittencourt
Michael T. Booker
Vaughn G. Braxton
Peter R. Carroll
David D. Casalino
Silvia D. Chang
Fergus V. Coakley
Ravjot Dhatt
Steven C. Eberhardt
Bryan R. Foster
Adam T. Froemming
Jurgen J. Fütterer
Dhakshina M. Ganeshan
Mark R. Gertner
Lori Mankowski Gettle
Sangeet Ghai
Rajan T. Gupta
Michael E. Hahn
Roozbeh Houshyar
Candice Kim
Chan Kyo Kim
Chandana Lall
Daniel J.A. Margolis
Charles E. McCulloch
Stephen E. McRae
Aytekin Oto
Rosaleen B. Parsons
Antonio C. Westphalen
Publication date
1 July 2020
Publisher
Health Sciences Research Commons
Abstract
© RSNA, 2020. Background: Prostate MRI is used widely in clinical care for guiding tissue sampling, active surveillance, and staging. The Prostate Imaging Reporting and Data System (PI-RADS) helps provide a standardized probabilistic approach for identifying clinically significant prostate cancer. Despite widespread use, the variability in performance of prostate MRI across practices remains unknown. Purpose: To estimate the positive predictive value (PPV) of PI-RADS for the detection of high-grade prostate cancer across imaging centers. Materials and Methods: This retrospective cross-sectional study was compliant with the HIPAA. Twenty-six centers with members in the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel submitted data from men with suspected or biopsy-proven untreated prostate cancer. MRI scans were obtained between January 2015 and April 2018. This was followed with targeted biopsy. Only men with at least one MRI lesion assigned a PI-RADS score of 2–5 were included. Outcome was prostate cancer with Gleason score (GS) greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2). A mixed-model logistic regression with institution and individuals as random effects was used to estimate overall PPVs. The variability of observed PPV of PI-RADS across imaging centers was described by using the median and interquartile range. Results: The authors evaluated 3449 men (mean age, 65 years 6 8 [standard deviation]) with 5082 lesions. Biopsy results showed 1698 cancers with GS greater than or equal to 3+4 (International Society of Urological Pathology grade group ≥2) in 2082 men. Across all centers, the estimated PPV was 35% (95% confidence interval [CI]: 27%, 43%) for a PI-RADS score greater than or equal to 3 and 49% (95% CI: 40%, 58%) for a PI-RADS score greater than or equal to 4. The interquartile ranges of PPV at these same PI-RADS score thresholds were 27%–44% and 27%–48%, respectively. Conclusion: The positive predictive value of the Prostate Imaging and Reporting Data System was low and varied widely across centers
Similar works
Full text
Available Versions
George Washington University: Health Sciences Research Commons (HSRC)
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:hsrc.himmelfarb.gwu.edu:sm...
Last time updated on 03/12/2020